Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2: A Narrative Review
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Accurate serologic tests to detect host antibodies to severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) will be critical for the public health response to the coronavirus disease 2019 pandemic. Many use cases are envisaged, including complementing molecular methods for diagnosis of active disease and estimating immunity for individuals. At the population level, carefully designed seroepidemiologic studies will aid in the characterization of transmission dynamics and refinement of disease burden estimates and will provide insight into the kinetics of humoral immunity. Yet, despite an explosion in the number and availability of serologic assays to test for antibodies against SARS-CoV-2, most have undergone minimal external validation to date. This hinders assay selection and implementation, as well as interpretation of study results. In addition, critical knowledge gaps remain regarding serologic correlates of protection from infection or disease, and the degree to which these assays cross-react with antibodies against related coronaviruses. This article discusses key use cases for SARS-CoV-2 antibody detection tests and their application to serologic studies, reviews currently available assays, highlights key areas of ongoing research, and proposes potential strategies for test implementation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020) · Science · doi:10.1126/science.abb3221 · Cited by 3,633
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769 · cited 3×
“Regarding SARS-CoV-2 ELISA using S1 protein epitopes, several pilot studies report positive results with sera from patients with SARS-CoV-1, and a lack of significant cross-reactivity when using sera from small numbers of patients seropositive for the endemic human coronaviruses (18, 44).”
BackgroundMethodResultOkba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614
Estimating the burden of SARS-CoV-2 in France
Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N., Richet, J., Dubost, C.-L., et al. (2020) · Science · doi:10.1126/science.abc3517 · Cited by 1,038
Liu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., Tan, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123158 · Cited by 830 · cited 12×
“Table 2—Continued Company and Location Assay Target Analyte Regulatory Status Sensitivity and Specificity (95% CI), % Population in Which Assay Was Evaluated Reference Specificity: 96.3 (89.7–99.2) 82 prepandemic sera (blood donors or other diseases) Sensitivity: 90.0 (74.4–96.5) NA 34 Specificity: 100.0 (95.4–100.0)…”
BackgroundInfluentialWu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020) · doi:10.1101/2020.03.30.20047365 · Cited by 754
Cited by
Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection
Dinnes, J., Deeks, J. J., Adriano, A., Berhane, S., Davenport, C., Dittrich, S., Emperador, D., Takwoingi, Y., Cunningham, J., Beese, S., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013705 · Cited by 1,156
Self-citationConsiderations for diagnostic COVID-19 tests
Vandenberg, O., Martiny, D., Rochas, O., van Belkum, A., & Kozlakidis, Z. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00461-z · Cited by 803
Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2: A Narrative Review
Cheng, M. P., Papenburg, J., Desjardins, M., Kanjilal, S., Quach, C., Libman, M., Dittrich, S., & Yansouni, C. P. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1301 · Cited by 593
Self-citationRapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection
Dinnes, J., Deeks, J. J., Berhane, S., Taylor, M., Adriano, A., Davenport, C., Dittrich, S., Emperador, D., Takwoingi, Y., Cunningham, J., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013705.pub2 · Cited by 591
Self-citationSubunit Vaccines Against Emerging Pathogenic Human Coronaviruses
Wang, N., Shang, J., Jiang, S., & Du, L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00298 · Cited by 425
Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020
Bajema, K. L., Wiegand, R. E., Cuffe, K., Patel, S. V., Iachan, R., Lim, T., Lee, A., Moyse, D., Havers, F. P., Harding, L., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.7976 · Cited by 276
Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis
Bobrovitz, N., Arora, R. K., Cao, C., Boucher, E., Liu, M., Donnici, C., Yanes-Lane, M., Whelan, M., Perlman-Arrow, S., Chen, J., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0252617 · Cited by 246
Self-citationSeroTracker: a global SARS-CoV-2 seroprevalence dashboard
Arora, R. K., Joseph, A., Van Wyk, J., Rocco, S., Atmaja, A., May, E., Yan, T., Bobrovitz, N., Chevrier, J., Cheng, M. P., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30631-9 · Cited by 200
Self-citation
Metadata
- Authors
- Cheng, M. P., Yansouni, C. P., Basta, N. E., Desjardins, M., Kanjilal, S., Paquette, K., Caya, C., Semret, M., Quach, C., Libman, M., Mazzola, L., Sacks, J. A., Dittrich, S., & Papenburg, J.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2020-09-15
- Volume
- 173
- Issue
- 6
- Pages
- 450-460
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W3033107971
- Cited by
- 135
- References
- 13
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.